Solid Organ Transplantation for HIV-Infected Individuals
- PMID: 29977166
- PMCID: PMC6028051
- DOI: 10.1007/s40506-018-0144-1
Solid Organ Transplantation for HIV-Infected Individuals
Abstract
Purpose of review: The prevalence of end-stage organ disease is increasing among HIV-infected (HIV+) individuals. Individuals with well-controlled HIV on antiretroviral therapy (ART), without active opportunistic infections or cancer, and with specified minimum CD4 cell counts are appropriate transplant candidates. Infectious disease clinicians can improve access to transplantation for these patients and optimize management pre- and post-transplant.
Recent findings: Clinical trials and registry-based studies demonstrate excellent outcomes for select HIV+ kidney and liver transplant recipients with similar patient and graft survival as HIV-uninfected patients. Elevated allograft rejection rates have been observed in HIV+ individuals; this may be related to a dysregulated immune system or drug interactions. Lymphocyte-depleting immunosuppression has been associated with lower rejection rates without increased infections using national registry data. Hepatitis C virus (HCV) coinfection has been associated with worse outcomes, however improvements are expected with direct-acting antivirals.
Summary: Solid organ transplantation should be considered for HIV+ individuals with end-stage organ disease. Infectious disease clinicians can optimize ART to avoid pharmacoenhancers, which interact with immunosuppression. The timing of HCV treatment (pre- or post-transplant) should be discussed with the transplant team. Finally, organs from HIV+ donors can now be considered for HIV+ transplant candidates, within research protocols.
Keywords: HIV infection; end-stage liver disease; end-stage renal disease; immunosuppression; kidney transplant; liver transplant; solid organ transplantation.
Conflict of interest statement
Conflict of Interest Ashton A. Shaffer declares that she has no conflict of interest. Christine M. Durand has received research grants from Bristol Meyers Squibb, Gilead Sciences, Merck Pharmaceuticals, and Viiv Healthcare, and has served as a scientific advisor for Bristol Meyers Squibb, Gilead Sciences, and Merck Pharmaceuticals.
Figures

Similar articles
-
Kidney and liver organ transplantation in persons with human immunodeficiency virus: An Evidence-Based Analysis.Ont Health Technol Assess Ser. 2010;10(4):1-56. Epub 2010 Mar 1. Ont Health Technol Assess Ser. 2010. PMID: 23074407 Free PMC article.
-
Solid Organ Transplantation in HIV-Infected Recipients: History, Progress, and Frontiers.Curr HIV/AIDS Rep. 2019 Jun;16(3):191-203. doi: 10.1007/s11904-019-00440-x. Curr HIV/AIDS Rep. 2019. PMID: 31093920 Free PMC article. Review.
-
Infections in solid organ transplantation in special situations: HIV-infection and immigration.Enferm Infecc Microbiol Clin. 2012 Mar;30 Suppl 2:76-85. doi: 10.1016/S0213-005X(12)70086-1. Enferm Infecc Microbiol Clin. 2012. PMID: 22542039 Review.
-
Infections in solid organ transplant HIV-infected patients.Clin Microbiol Infect. 2014 Sep;20 Suppl 7:119-30. doi: 10.1111/1469-0691.12754. Clin Microbiol Infect. 2014. PMID: 25040016 Review.
-
Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study.Transplantation. 2003 Jul 27;76(2):370-5. doi: 10.1097/01.TP.0000075973.73064.A6. Transplantation. 2003. PMID: 12883195 Clinical Trial.
Cited by
-
Role of the pharmacist caring for people at risk of or living with HIV in Canada.Can Pharm J (Ott). 2024 Aug 2;157(5):218-239. doi: 10.1177/17151635241267350. eCollection 2024 Sep-Oct. Can Pharm J (Ott). 2024. PMID: 39310805 Free PMC article. No abstract available.
-
Racial Disparities in Access to the Kidney Transplant Waitlist Among People with Human Immunodeficiency Virus.AIDS Patient Care STDS. 2023 Aug;37(8):394-402. doi: 10.1089/apc.2023.0037. AIDS Patient Care STDS. 2023. PMID: 37566535 Free PMC article.
-
Challenges in solid organ transplantation in people living with HIV.Intensive Care Med. 2019 Mar;45(3):398-400. doi: 10.1007/s00134-019-05524-1. Epub 2019 Jan 14. Intensive Care Med. 2019. PMID: 30637443 No abstract available.
-
A prospective multicenter pilot study of HIV-positive deceased donor to HIV-positive recipient kidney transplantation: HOPE in action.Am J Transplant. 2021 May;21(5):1754-1764. doi: 10.1111/ajt.16205. Epub 2020 Aug 8. Am J Transplant. 2021. PMID: 32701209 Free PMC article.
-
Outcomes of donor-derived superinfection screening in HIV-positive to HIV-positive kidney and liver transplantation: a multicentre, prospective, observational study.Lancet HIV. 2020 Sep;7(9):e611-e619. doi: 10.1016/S2352-3018(20)30200-9. Epub 2020 Jul 27. Lancet HIV. 2020. PMID: 32730756 Free PMC article.
References
-
- Prevention. CfDCa. Hiv surveillance report, 2014. 26
-
- Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. Hiv outpatient study investigators. N Engl J Med. 1998;338(13):853–860. - PubMed
-
- Losina E, Freedberg KA. Life expectancy in hiv. BMJ. 2011;343(d6015) - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials